Gh Research Plc GHRS

$18.44 -1.49 (-7.48%)

Valuation

Market cap
1,367,377,000
Revenue TTM
$0
Net income TTM
$-48,260,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
407,200
Avg volume
295,054
Day's range
$18.32 – $19.88
Shares out
68,609,000
Stochastic %K
9%
Beta
1.31
Analysts
Strong Buy
Price target
$42.89

Price

Company profile

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpar...

Show more

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Industry
Biotechnology
Sector
Healthcare
Phone
353 1 437 8334
Website
https://www.ghres.com
Address
Joshua Dawson House, Dawson Street, Dublin, Ireland

Latest news

Stocktwits

Mokksen Nov 5, 3:51 PM
$GHRS ouch this is getting hit harder than its peers…..again. Retail getting zapped :D
1 replies
putINwork Nov 5, 12:17 PM
$GHRS the only one red in the entire sector. People are realizing no matter how well this does a bronchospasm warning will send doctors running for the hills and it will flop just like ADASUVE. There is still time to get into literally anywhere else. HELP and CMPS are at bargain prices now!!
0 replies
leLu83 Nov 5, 3:16 AM
$GHRS GHRS Remains the Short-Term Spike Leader: GH Research holds the highest single-dose, short-term placebo-adjusted point drop (-15.5) at the 1-week mark. Because it is inhaled 5-MeO-DMT, the onset is incredibly fast.
1 replies
leLu83 Nov 5, 3:15 AM
$GHRS GH Research's double-blind placebo-adjusted drop of 15.5 points in just over a week places GH001 among the most powerful fast-acting data sets in the treatment-resistant space, drawing favorable early phase comparisons from executives to existing treatments like Spravato
0 replies
putINwork Nov 3, 5:51 PM
$GHRS look everyone is moving out of GHRS and into the other non-inhalation meds in the sector. FDA is going to approve this with a bronchospasm warning and destroy any clinical utility. Not worth a lawsuit from a Doctor’s viewpoint
1 replies
putINwork Nov 3, 5:48 PM
$GHRS look share price is falling bc people are getting out while they still can, once that bronchospasm warning hits you’re done - approval or not
0 replies
putINwork Nov 3, 5:46 PM
$GHRS everyone I work with in the hospital thinks this is a joke, inhalation meds don’t work in psychiatry. “Risk my patient getting asthma when there are sublingual or PO options?!!” Never. Scientists don’t understand real clinical application - get out while you can to CMPS and HELP - there is only disappointment when the FDA puts a bronchospasm warning on this with its approval. No one will use it.
1 replies
leLu83 Nov 3, 5:24 PM
$GHRS RBC Cap Markets is rated the #1 research tute in Canada. Brian Abrahams states GHRS is the next follow through with big pharma. He is lead biotech analyst and holds and MD from Albert Einstein of Medicine. Undergrad from Yale. Hes not just pushing trade whispers. Previpus stops at wells fargo and jefferies. FACTS. both Abbvie and JJ were finalists for ATAI, but both wanted the single asset, not ATAI multi faceted portfolio. Guess who fits that to a T? GHRS With a small OS under 70M. No debt. 360M in cash. It has the besr balance sheet in the sector. And the madrs scores? Tops. 11 min duration? Tops. 1 hour discharge? Tops. Multi decade leaders from JJ jumping ship to GHRS? The pioneers of Spravato? Check and check. Free money 💰 🤑
0 replies